To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Already have an account?
Oncolytics Biotech® Inc.'s Research Collaborators to Present Data on REOLYSIN® Clinical Trials
Read time: Less than a minute
Oncolytics Biotech Inc. has announced that data from three clinical trials using REOLYSIN are scheduled to be presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting will take place in Orlando, Florida May 29-June 2, 2009. The abstracts are available on the ASCO website at
www.asco.org
.
REOLYSIN poster presentations:
Dr. Monica Mita and colleagues are scheduled to deliver a poster presentation entitled "A Phase II Study of Intravenous (IV) Wild-Type Reovirus in the Treatment of Patients with Bone and Soft Tissue Sarcomas Metastatic to the Lung."
Dr. Johann de Bono and colleagues are scheduled to deliver a poster presentation entitled "A Phase I Study of the Combination of Intravenous Reolysin (REO) and Gemcitabine (GEM) in Patients (pts) with Advanced Cancer."
Dr. Sanjay Goel and colleagues are scheduled to deliver a poster entitled "Dose Escalation and Pharmacodynamic Study of Intravenous Administration of REOLYSIN, a Live Replication Competent RNA Virus in Patients with Advanced Solid Tumors."
Dr. Monica Mita and colleagues are scheduled to deliver a poster presentation entitled "A Phase II Study of Intravenous (IV) Wild-Type Reovirus in the Treatment of Patients with Bone and Soft Tissue Sarcomas Metastatic to the Lung."
Dr. Johann de Bono and colleagues are scheduled to deliver a poster presentation entitled "A Phase I Study of the Combination of Intravenous Reolysin (REO) and Gemcitabine (GEM) in Patients (pts) with Advanced Cancer."
Dr. Sanjay Goel and colleagues are scheduled to deliver a poster entitled "Dose Escalation and Pharmacodynamic Study of Intravenous Administration of REOLYSIN, a Live Replication Competent RNA Virus in Patients with Advanced Solid Tumors."
